Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

Lysophospholipids like LPA and S1P are important for hair growth, immune responses, and vascular development, and could be targeted for treating diseases.

sPLA2-IIA increases growth in hair follicle stem cells and cancer cells, suggesting it could be targeted for hair growth and cancer treatment.

Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.

Organoids help study and treat genetic diseases, offering personalized medicine and therapy testing.

Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.

PGD2 increases androgen receptor activity in hair cells, which could be targeted to treat hair loss.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

Keratins are crucial for tissue strength, and mutations in keratin genes can lead to various diseases, highlighting the need for targeted therapies.

Nanoparticulate systems improve drug delivery by controlling release, protecting drugs, changing absorption and distribution, and concentrating drugs in targeted areas.

Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.

Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.

The research found that specific stem cells maintain skin gland openings and that disrupting their activity can cause blockages or early cancer signs, indicating a need for targeted treatments.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

Skin fat has important roles in hair growth, skin repair, immune defense, and aging, and could be targeted for skin and hair treatments.

EGFR helps protect hair follicles from bacterial infections.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

A new treatment using a DNA aptamer can promote hair growth by targeting a specific receptor.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Multiple treatments work best for hair loss.

Lipid nanoparticles improve treatment delivery and are key to future therapies, but challenges in manufacturing and safety remain.

Activating the GDNF-GFRα1-RET signaling pathway could potentially promote skin and limb regeneration in humans and could be used to treat hair loss and promote wound healing.

Spanlastics improve drug delivery by enhancing bioavailability and targeting, reducing side effects.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Classifying alopecia helps diagnose and treat different types of hair loss accurately.

A new engineered treatment shows promise in curing heart fibrosis.